Clinical trials testing MDM2 inhibition in combination with immunotherapy
| Cancer entity . | Design . | MDM2 inhibitor . | Immunotherapy . | Number of participants . | NCT number . |
|---|---|---|---|---|---|
| AML | Siremadlin (HDM201) alone and in combination with DLI in AML after allo-HCT | Siremadlin (HDM201) | Allo-HCT, DLI | 38 | NCT05447663 |
| AML, MDS | Phase 1b, multiarm, open-label study of HDM201 in combination with MBG453 or venetoclax for AML or MDS | Siremadlin (HDM201) | MBG453 (anti–TIM-3 antibody) | 52 | NCT03940352 |
| CRC, NSCLC, BC, RCC | Phase 1b study of spartalizumab in combination with HDM201 or LCL161 or everolimus or panobinostat | Siremadlin (HDM201) | Spartalizumab (anti–PD-1 antibody) | 298 | NCT02890069 |
| Advanced liposarcoma or other advanced solid tumors | Phase 1b APG-115 in combination with PD-1 inhibitor in patients with advanced liposarcoma or advanced solid tumors | APG-115 | Anti–PD-1 antibody | 92 | NCT04785196 |
| Metastatic melanoma or other advanced solid tumors | Phase 1b (part 1) and phase 2 (part 2) APG-115 in combination with pembrolizumab in patients with metastatic melanomas or advanced solid tumors | APG-115 | Pembrolizumab anti–PD-1 antibody | 224 | NCT03611868 |
| Solid tumors | Phase 2 (solid tumors) to test different doses of BI 907828 in combination with ezabenlimab, with or without BI 754111 | BI-907828 | BI 754091 (anti–PD-1) with/without BI 754111 (anti–LAG-3) | 140 | NCT03964233 |
| CRC | Phase 1b/2, open-label, multicenter, randomized study designed to assess the safety and preliminary antitumor activity | Idasanutlin (RG7388) | Atezolizumab (anti–PD-L1) | 94 | NCT03555149 Study terminated |
| Cancer entity . | Design . | MDM2 inhibitor . | Immunotherapy . | Number of participants . | NCT number . |
|---|---|---|---|---|---|
| AML | Siremadlin (HDM201) alone and in combination with DLI in AML after allo-HCT | Siremadlin (HDM201) | Allo-HCT, DLI | 38 | NCT05447663 |
| AML, MDS | Phase 1b, multiarm, open-label study of HDM201 in combination with MBG453 or venetoclax for AML or MDS | Siremadlin (HDM201) | MBG453 (anti–TIM-3 antibody) | 52 | NCT03940352 |
| CRC, NSCLC, BC, RCC | Phase 1b study of spartalizumab in combination with HDM201 or LCL161 or everolimus or panobinostat | Siremadlin (HDM201) | Spartalizumab (anti–PD-1 antibody) | 298 | NCT02890069 |
| Advanced liposarcoma or other advanced solid tumors | Phase 1b APG-115 in combination with PD-1 inhibitor in patients with advanced liposarcoma or advanced solid tumors | APG-115 | Anti–PD-1 antibody | 92 | NCT04785196 |
| Metastatic melanoma or other advanced solid tumors | Phase 1b (part 1) and phase 2 (part 2) APG-115 in combination with pembrolizumab in patients with metastatic melanomas or advanced solid tumors | APG-115 | Pembrolizumab anti–PD-1 antibody | 224 | NCT03611868 |
| Solid tumors | Phase 2 (solid tumors) to test different doses of BI 907828 in combination with ezabenlimab, with or without BI 754111 | BI-907828 | BI 754091 (anti–PD-1) with/without BI 754111 (anti–LAG-3) | 140 | NCT03964233 |
| CRC | Phase 1b/2, open-label, multicenter, randomized study designed to assess the safety and preliminary antitumor activity | Idasanutlin (RG7388) | Atezolizumab (anti–PD-L1) | 94 | NCT03555149 Study terminated |
BC, breast cancer; CRC, colorectal cancer; DLI, donor lymphocyte infusion; NSCLC, non–small cell lung cancer; RCC, renal cell carcinoma.